While there has been great progress in understanding the risk architecture of autism, there are still unanswered questions about the nature of the genetic and non-genetic risk for autism. Many of these questions can be best addressed with a population-based epidemiological sample with detailed demographic and environmental information. To date, almost all studies on the etiology of autism relied on convenience samples, which are subject to biases in capturing genetic and, possibly even more so, environmental risk. Epidemiologically based samples provide a unique resource to identify genetic and non-genetic causes of autism, while allowing for a precise estimate of risk in the population attributed to each source of risk. Sweden benefits from a centralized medical system that has been the foundation of large-scale epidemiological studies in psychiatric disorders, particularly schizophrenia and bipolar disorder. In our opinion, the significance of this proposal lies in the value of a unique, population-based epidemiological sample, analyzed in such a way as to address several outstanding issues in autism. These include: 1) better estimates of heritability and environment in autism;2) assessing the rate of recurrent risk CNV in autism;3) discovery of rare standing single nucleotide variation in autism;4) dissection of mechanisms underlying the association of non-genetic findings with autism-and the discovery of novel environmental associations;and, 5) cross-disorder analyses to better understand shared liability to autism and schizophrenia.
The aims are: 1) To ascertain and biobank at least 1300 cases with autistic disorder and 1000 additional controls, to develop an international resource for ASD, and to assess selected, putative risk factors;2) To genotype all samples using high-density SNP arrays, including dense exome coverage, and sequence all trios using whole-exome approaches;and, 3) To use novel methods to assess the role of inherited and de novo variants in autism and to evaluate rare standing variation in autism, while integrating key environmental variables. In later years the relationship between autism risk and risk for schizophrenia will be assessed. The proposed research is innovative, in our opinion, because it ascertains autism samples in an epidemiologically valid manner, targeting a genetically homogenous population, for which schizophrenia and bipolar samples have already been collected. The proposal is also innovative in the use of novel methods to estimate heritability and to identify rare, standing variation conferring risk to autism, while providing an integrated model for genetics and environment in autism. Finally, the application is innovative, in our opinion, in that it provides he groundwork for understanding shared risk across autism and schizophrenia, making use of a homogenous group to have better power to identify shared risk. This new and substantively different approach to studying autism, compared to studies carried out in convenience samples, addresses many of the open questions in autism research and provides a path towards a better understanding of the risk factors for autism and ultimately to better interventions in autism.

Public Health Relevance

The proposed research is relevant to public health because a better understanding of risk in autism will lead to improved methods for prevention and treatment. It is also relevant to the NIH mission and to the IACC recommendations around epidemiological studies collecting and jointly analyzing genetic and environmental data in autism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH097849-01A1
Application #
8762250
Study Section
Behavioral Genetics and Epidemiology Study Section (BGES)
Program Officer
Addington, Anjene M
Project Start
2014-07-01
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Psychiatry
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Yip, Benjamin Hon Kei; Bai, Dan; Mahjani, Behrang et al. (2018) Heritable Variation, With Little or No Maternal Effect, Accounts for Recurrence Risk to Autism Spectrum Disorder in Sweden. Biol Psychiatry 83:589-597
Arora, Manish; Reichenberg, Abraham; Willfors, Charlotte et al. (2017) Fetal and postnatal metal dysregulation in autism. Nat Commun 8:15493
Kosmicki, Jack A; Samocha, Kaitlin E; Howrigan, Daniel P et al. (2017) Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet 49:504-510
Lim, Elaine T; Uddin, Mohammed; De Rubeis, Silvia et al. (2017) Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. Nat Neurosci 20:1217-1224
Sanders, Stephan J; He, Xin; Willsey, A Jeremy et al. (2015) Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron 87:1215-1233
Buxbaum, Joseph D (2015) DSM-5 and psychiatric genetics - round hole, meet square peg. Biol Psychiatry 77:766-8
De Rubeis, Silvia; He, Xin; Goldberg, Arthur P et al. (2014) Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515:209-15
Sandin, Sven; Lichtenstein, Paul; Kuja-Halkola, Ralf et al. (2014) The familial risk of autism. JAMA 311:1770-7
Gaugler, Trent; Klei, Lambertus; Sanders, Stephan J et al. (2014) Most genetic risk for autism resides with common variation. Nat Genet 46:881-5
Poultney, Christopher S; Goldberg, Arthur P; Drapeau, Elodie et al. (2013) Identification of small exonic CNV from whole-exome sequence data and application to autism spectrum disorder. Am J Hum Genet 93:607-19